← Eichor
Condition: Advanced Malignant Tumors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Malignant Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Phase 1/Phase 2 · 11 location(s) · National Health Research Institutes, Taiwan · NCT05048901Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT04778839Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
Phase 1 · 1 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07482592An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+
Phase 1 · 1 location(s) · China Medical University, China · NCT06013111Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100a Single-arm, Single-center, Open Clinical Study
Phase N/A · 1 location(s) · Beijing Geekgene Technology Co., LTD · NCT06431100A Study of TYK-00540 in Adult Patients With Solid Tumors
Phase 1 · 1 location(s) · TYK Medicines, Inc · NCT06246071Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Trutino Biosciences Inc. · NCT06770764A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Phase 1 · 10 location(s) · Janssen Research & Development, LLC · NCT07107230HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Hangzhou Hanx Biopharmaceuticals, Ltd. · NCT06708663A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Phase 1 · 19 location(s) · Merck Sharp & Dohme LLC · NCT07247110A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injectio
Phase 1 · 65 location(s) · GlaxoSmithKline · NCT06431594STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Phase 1/Phase 2 · 1 location(s) · Angela Y. Jia, MD PhD · NCT06574880A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harbor
Phase 2 · 31 location(s) · Allist Pharmaceuticals, Inc. · NCT06008288A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
Phase 1/Phase 2 · 1 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT05991583A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Vibrant Sciences Limited · NCT07222969Anti-GD2 ADC M3554 in Advanced Solid Tumors
Phase 1 · 11 location(s) · EMD Serono Research & Development Institute, Inc. · NCT06641908First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT07265622Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Hist
Phase 2 · 4 location(s) · Emory University · NCT05756569A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
Phase 1/Phase 2 · 9 location(s) · DualityBio Inc. · NCT07263594Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT07156253Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Phase 1 · 2 location(s) · Chipscreen Biosciences, Ltd. · NCT06902350Safety and Preliminary Efficacy of Anti-CDH17 CAR-T Cell Therapy in Patients with CDH17-positive Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06820424Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · TCRCure Biopharma Ltd. · NCT07487597A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
Phase 1 · 19 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT06859762Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Phase 1/Phase 2 · 5 location(s) · Anbogen Therapeutics, Inc. · NCT05532696
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.